CD55缺陷蛋白丢失肠病治疗药物——帕泽利单抗  

Therapeutic drug for CD55-deficient protein-losing enteropathy:pozelimab

作　　者：张嘉珊 赵志刚[2] ZHANG Jia-shan;ZHAO Zhi-gang(Department of Pharmacy,Beijing Health Vocational College,Beijing 101101,China;Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China)

机构地区：[1]北京卫生职业学院药学系,北京101101 [2]首都医科大学附属北京天坛医院药学部,北京100070

出　　处：《临床药物治疗杂志》2024年第1期22-25,共4页Clinical Medication Journal

摘　　要：帕泽利单抗是一种全人源单克隆抗体,该药阻断补体因子C5的活性,抑制膜攻击复合体的形成,可预防治疗补体系统异常介导的疾病。2023年8月18日帕泽利单抗由FDA批准上市,用于治疗1岁及以上的CD55缺陷蛋白丢失肠病患者。本文对帕泽利单抗的药理作用、药效学、药动学和临床疗效及安全性等方面进行综述,旨在为临床用药提供参考。Pozelimab is a fully human monoclonal antibody designed to block the activity of complement factor C5 and prevent diseases mediated by the complement pathway.FDA approved pozelimab,a complement inhibitor,for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy(PLE),also known as CHAPLE disease on August 18th,2023.This article reviews the mechanism of action,pharmacodynamics,pharmacokinetics,clinical efficacy and safety of pozelimab,to provide a reference for its clinical use.

关 键 词：帕泽利单抗 CD55缺陷蛋白丢失肠病 补体抑制剂 

分 类 号：R979.9[医药卫生—药品]